Bragar Eagel & Squire Investigates Praxis and Other Stocks
Investigation Overview by Bragar Eagel & Squire
Bragar Eagel & Squire, P.C., a prominent firm in the realm of shareholder rights, is currently probing potential legal claims linked to Praxis Precision Medicines, Inc. (NASDAQ: PRAX), Align Technology, Inc. (NASDAQ: ALGN), Lantheus Holdings, Inc. (NASDAQ: LNTH), and Spirit Aviation Holdings, Inc. (NYSE: FLYY). The focus of these investigations is to determine if these entities may have contravened federal securities laws or engaged in any deceptive business practices.
Praxis Precision Medicines, Inc.
Praxis has recently been under scrutiny following a significant announcement regarding its second quarter financial results. In this report, they shared the latest findings from a mid-stage study concerning their anti-seizure medication, vormatrigine. Alarmingly, out of a pool of 61 patients, 36 faced treatment-emergent adverse events, leading to the withdrawal of nearly 25% of participants from the study.
This news prompted a steep decline in Praxis’ share price, which dropped by $3.00, translating to a 5.55% decrease, finishing at $51.09 per share on the day of the announcement.
Align Technology, Inc.
The investigation into Align Technology revolves around allegations of misleading statements and the possible omission of critical information affecting investors. After disclosing its second-quarter financial results on July 30, 2025, Align failed to meet both analyst forecasts and its own revenue guidance. They subsequently adjusted their revenue expectations downward for the upcoming quarter, resulting in a staggering drop of almost 37% in share price following the announcement.
Lantheus Holdings, Inc.
Lantheus recently revealed disappointing second-quarter performance, where they disclosed earnings-per-share (EPS) and revenue figures falling short of expectations. Moreover, the company slashed its full-year revenue guidance significantly from a range of $1.550 billion - $1.585 billion down to $1.475 billion - $1.51 billion. The CEO attributed these setbacks to increased pricing pressures within the PSMA PET market and strategic decisions made to prioritize long-term franchise value over immediate volume.
Consequently, Lantheus’s stock took a major hit, dropping $20.76 or 28.58%, culminating in a close of $51.87 per share.
Spirit Aviation Holdings, Inc.
Spirit Aviation's situation has also sparked concern following a regulatory filing on August 11, 2025, which expressed substantial doubt regarding the company's ability to operate as a going concern within the next year. This filing highlighted adverse market conditions alongside specific liquidity covenants in their financial agreements that necessitate an uptick in financial results faster than what the company currently anticipates. Following this alarming revelation, Spirit's share price plummeted by $1.44, a drastic 40.68% decrease, closing at just $2.10.
Conclusion and What Investors Should Know
Bragar Eagel & Squire, P.C. continues to advocate for investors impacted by these developments. Should you have any queries regarding your investment in these companies or require legal counsel, please consider reaching out to our firm. We are dedicated to protecting the rights of shareholders and ensuring that justice is served.
Contact Information
If you need professional legal assistance or have further inquiries, reach us directly:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Frequently Asked Questions
What is the focus of Bragar Eagel & Squire's investigation?
The focus is on potential claims against firms like Praxis, Align, Lantheus, and Spirit for possible violations of securities laws or deceptive business practices.
What were the major findings from Praxis's recent report?
Praxis reported high rates of treatment-emergent adverse events in its vormatrigine study, leading to significant investor concern and a drop in share price.
How did Align Technology's revenue guidance affect its stock price?
Align's revised revenue guidance led to a nearly 37% decrease in stock price due to missed analyst expectations.
What issues affected Lantheus Holdings in their recent quarter?
Lantheus disclosed disappointing earnings and lowered revenue guidance, resulting in a sharp decline in share value.
What should investors do if they have been affected?
Investors are encouraged to contact Bragar Eagel & Squire, P.C. for legal assistance regarding their investments.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.